ClinicalTrials.Veeva

Menu
T

The Urology Place | San Antonio, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relugolix
64Cu
Androgen
AU-011
Belzupacap Sarotalocan
Leuprolide Acetate
Copper Cu 64
Darolutamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 14 total trials

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer (AMPLIFY)

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Enrolling
Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Prostate Cancer Patients Treated by Radiotherapy
Drug: 64Cu-SAR-bisPSMA

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer...

Enrolling
Non-muscle-invasive Bladder Cancer
Non-Muscle Invasive Bladder Carcinoma
Combination Product: AU-011 in Combination with Medical Laser Administration
Drug: AU-011
Locations recently updated

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Active, not recruiting
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfa...

Enrolling
Prostate Adenocarcinoma
Prostate Cancer
Drug: Copper Cu 64 PSMA I&T
Locations recently updated

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Enrolling
Prostatic Neoplasms
Prostate Cancer
Drug: 64Cu-SAR-bisPSMA

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Enrolling
Benign Prostatic Hyperplasia (BPH)
Procedure: UroLift
Device: iTind

The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

Active, not recruiting
Urinary Urge Incontinence
Device: Revi System - Delayed Activation
Device: Revi System Treatment

This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemi...

Active, not recruiting
Prostate Cancer Recurrent
Biological: RV001V
Other: Placebo

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with G...

Active, not recruiting
Prostate Cancer
Device: Vanquish System

Trial sponsors

C
Sumitomo Pharma logo
Aura Biosciences logo
Bayer logo
B
C
F
ImmunityBio logo
O
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems